CXCR1 - Human IL-8 Receptor cDNA
A plasmid encodes human interleukin-8 (IL-8) receptor CXCR1. IL-8 is a chemo-attractant cytokine that attracts and activates neutrophils in inflammatory regions.
Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions
Summary:
The National Cancer Institute (NCI) seeks licensees for the further development of a family of novel iodonium analogs as therapeutics for cancer and/or chronic inflammatory conditions.
Synergistic Interactions for Improved Cancer Treatment
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer.
LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders
Use of Leucine Rich Repeat Kinase 2 (LRRK2) inhibitors for the treatment of Intestinal Bowel Disorders (IBD) is disclosed. IBD is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Crohn's disease and ulcerative colitis, two common forms of idiopathic IBD, are chronic, relapsing inflammatory disorders of the gastrointestinal tract.
Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies
Summary:
The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways.
Novel Kinase Inhibitory Aplithianines
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:
Reverse Thiazine Kinase Inhibitors
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:
Novel Kinase Inhibitory Thiazines
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:
Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and licensees for a panel of five fully human antibodies against CD276 for the treatment of solid tumors. The collection also includes human CARs incorporating the antibodies for immunotherapeutic use.
Machine Learning Model for the Prioritization of Cancer Neoepitopes
Summary:
The National Cancer Institute (NCI) seeks licensees for a machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy.